Advantages of Using Y-90 for the First-Line Treatment of Patients With Liver Metastases from mCRC

Dirk Arnold, MD

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the advantages of using yttrium-90 (Y-90) as the first line treatment for patients with liver metastases from metastatic colorectal cancer (mCRC).

Arnold describes how Y-90 brings the active compound directly to the liver metastases, so that chemotherapy is not needed. This is beneficial, since chemotherapy does not always work.

He also gives an overview of the toxicities that were presented in the phase III SIRFLOX study. A possible long term adverse event is liver damage, but Arnold and his colleagues must wait for these results.

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the advantages of using yttrium-90 (Y-90) as the first line treatment for patients with liver metastases from metastatic colorectal cancer (mCRC).